Nektar Therapeutics (NKTR) Short term Debt (2011 - 2020)
Nektar Therapeutics (NKTR) recorded quarterly Short term Debt of $254.1 million in Q1 2020, little changed quarter-over-quarter from $252.9 million in Q4 2019.
Nektar Therapeutics (NKTR) Short term Debt (2011 - 2020) Analysis & Trends
Nektar Therapeutics' Short term Debt history runs 5 years deep, the most recent figure standing at $254.1 million for Q1 2020.
- In Q1 2020, Short term Debt changed N/A year-over-year to $254.1 million; the TTM figure through Mar 2020 stood at $254.1 million (changed N/A YoY), while the FY2019 annual figure was $252.9 million, changed N/A from the prior year.
- Short term Debt was $254.1 million for Q1 2020 at Nektar Therapeutics, roughly flat from $252.9 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $254.1 million in Q1 2020 to a low of $252.9 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Nektar Therapeutics | 1.51 Bn | 939.55 Mn | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 254.14 Mn |
| Dec 31, 2019 | 252.89 Mn |
| Sep 30, 2015 | 125.00 Mn |
| Mar 31, 2012 | 214.96 Mn |
| Dec 31, 2011 | 214.96 Mn |
| Sep 30, 2011 | 214.96 Mn |